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1083Patients with atrial ﬁbrillation (AF) who undergo car-
dioversion are at risk for thromboembolic events (1–3), and
vitamin K antagonists appear to lower this risk (4–7).
Anticoagulation with an international normalized ratio of
2.0 to 3.0 is currently recommended for 3 weeks before
elective cardioversion and is to be continued for a minimum
of 4 weeks after cardioversion (8). Dabigatran, a direct
thrombin inhibitor, appears to have efﬁcacy comparable to
that of warfarin in selected patients after cardioversion (9).See page 1088The factor Xa inhibitor apixaban, when compared with
warfarin, has been shown to reduce the risk of stroke and
systemic emboli in patients with AF and risk factors for
stroke in the ARISTOTLE (Apixaban for Reduction in
Stroke and Other Thromboembolic Events in Atrial
Fibrillation) trial (10). The effectiveness of apixaban for
prevention of stroke in patients undergoing cardioversion is
unknown. The aim of the present analysis was to compare
the baseline characteristics of patients undergoing car-
dioversion with those not undergoing cardioversion, describe
the duration of anticoagulation before cardioversion, and
examine the rate of major clinical events, including stroke,
systemic embolism, myocardial infarction (MI), major
bleeding, and death, in these patients.Methods
Studypopulation. The design and results of the ARISTOTLE
trial have been previously reported (10,11). In brief, patients
eligible for this trial had AF documented by electrocardiography
at the time of enrollment or, if not in AF at the time of
enrollment, had AF documented on 2 occasions at least 2 weeks
apart within the 12 months before enrollment. Documentation
of AF was by electrocardiogram or rhythm strip, Holter monitor,
or intracardiac recording and lasted longer than 1 min. In
addition, at least 1 of the following risk factors for stroke was
required: age 75 years; previous stroke, transient ischemic
attack, or systemic embolism; symptomatic heart failure within
the previous 3 months or left ventricular ejection fraction 40%;
and diabetes or hypertension requiring pharmacological therapy.
Key exclusion criteria were AF due to a reversible cause,Dr. Garcia has received consulting fees from Boehringer Ingelheim, Bristol-Myers
Squibb, Daiichi Sankyo, Pﬁzer Inc., Roche Diagnostics, and CSL Behring; and has
received fees for the development of educational materials from Boehringer Ingelheim.
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and Pﬁzer Inc. Dr. Harjola has received consulting and lecture fees from Abbott
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Novartis, and Orion Pharma. Dr. Rosenqvist has received honoraria from Bristol-
Myers Squibb/Pﬁzer Inc. Dr. Alexander has received research support through
Duke University from Bristol-Myers Squibb, CSL Behring, Pﬁzer Inc., Phyxiusmoderate or severe mitral stenosis,
conditions other than AF that re-
quired anticoagulation (e.g., a pros-
thetic heart valve), stroke within the
previous 7 days, a need for aspirin
>165 mg/day or for both aspirin
and clopidogrel, and renal insufﬁciency with a creatinine level
>2.5 mg/dl or a creatinine clearance <25 ml/min.
Randomization. Patients were randomized to receive
either warfarin or apixaban. Warfarin was adjusted to ach-
ieve a target international normalized ratio of 2.0 to 3.0.
Apixaban was administered at dosages of 5 mg twice daily
or 2.5 mg twice daily in patients who had 2 or more of the
following criteria: age 80 years, body weight 60 kg, or
serum creatinine level 1.5 mg/dl.
Clinical outcomes. The primary efﬁcacy outcome of the
study was stroke, deﬁned as the abrupt onset of a non-
traumatic, focal neurological deﬁcit lasting at least 24 h, or
systemic embolism, deﬁned as symptoms consistent with
acute loss of blood to a noncerebral artery conﬁrmed by
autopsy, angiography, vascular imaging, or some other
objective testing. Secondary endpoints included MI and
death.MI was deﬁned as symptoms with biomarker elevation
at least 2 times greater than normal (creatine kinase, creatine
kinase-myocardial band, or troponin) or with new Q waves
in2 contiguous leads. Death was classiﬁed as cardiovascular
(stroke, systemic embolism, MI, sudden death, heart failure,
or indeterminate) or noncardiovascular. The primary safety
outcome was major bleeding as deﬁned by the International
Society of Thrombosis and Haemostasis (12). All primary
and secondary outcomes were adjudicated by a clinical events
committee blinded to treatment assignment.
Cardioversion. For this post-hoc analysis, all patients who
underwent cardioversion for AF in the ARISTOTLE trial
were identiﬁed by a case report form completed at the center
of enrollment. During the study, investigators were asked
to continue randomized therapy before and after the
procedure but had the option to suspend study medication
for open-label warfarin during cardioversion. The number of
patients undergoing cardioversion on assigned study medi-
cation was determined. The duration of anticoagulant
therapy before and after cardioversion was assessed, and
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1084MI, major bleeding, and death, were assessed during the
follow-up period. Because strokes or systemic emboli may
occur several days to weeks after cardioversion, likely due to
restoration of mechanical function of the atria, a 30-day
follow-up period was used to capture these events and to
preserve a temporal correlation to the procedure.
Statistical analysis. The baseline characteristics of those
patients who underwent cardioversion for AF were
compared with noncardioverted patients, and baseline
characteristics in patients were compared according to
randomized treatment. Continuous variables are presented
as mean  SD with between-group comparisons. Student
t tests were used for normally distributed data and
nonparametric (Wilcoxon) tests for other data. Categorical
variables are presented as counts and percentages and
compared by chi-square tests or Fisher exact tests where
appropriate.
Clinical events are reported as the number of ﬁrst, unique
events in the 30 days after cardioversion. The occurrence of
1 event did not preclude the counting of another event
except for the inherent competing risk of mortality, after
which no event could be observed. The proportion of such
events out of the total number of cardioversions is also re-
ported. Hence, a patient with multiple cardioversions could
experience multiple MI events and each would be counted,
although only the ﬁrst MI event was counted among
multiple MI events after a single cardioversion. Events are
unique, meaning that a single event occurring within 30 days
of multiple cardioversions would only be counted once.
Thus, the results are descriptive of the sample and qualitative
comparisons are made but inference is limited.
The investigators had the option to temporarily suspend
study medication before cardioversion (likely to place the
patient on open-label warfarin). We conducted an intention-
to-treat style comparison according to randomized treatment
as our primary method of analysis. This was designed to
preserve randomization (as much as possible in a post-
randomization cohort) and capture potential inﬂuences of
randomized treatment that might be active before or after the
procedure. An on-treatment analysis, including only those
patients receiving study medications (apixaban or warfarin) or
warfarin at the time of cardioversion, was also performed.
Results
A total of 18,201 patients were enrolled in the ARISTOTLE
trial, and 743 cardioversions were performed in 540 patients.
At baseline, the principal investigator classiﬁed AF as
paroxysmal in 2,786 patients and either persistent or
permanent in 15,412 patients. A total of 414 patients
underwent 1 cardioversion, 87 underwent 2 cardioversions,
and 39 underwent 3 cardioversions. Seventy-ﬁve percent
of the procedures occurred during the ﬁrst year of follow-up.
The mean time from study entry to ﬁrst cardioversion for
patients assigned to warfarin was 243  231 days and for
patients assigned to apixaban was 251  248 days. Theminimum duration of therapy before cardioversion was
4 days for warfarin and 1 day for apixaban. The median time
in therapeutic range for patients undergoing cardioversion
was 59% (quartile 1: 42%, quartile 3: 73%). At the time of
cardioversion, 80% of patients assigned to warfarin and 84%
assigned to apixaban were taking the assigned study drug.
Open-label warfarin was used in 3.9% of patients assigned
to warfarin and in 3.6% of patients assigned to apixaban.
The anticoagulation status of the remaining patients was
uncertain.
Baseline characteristics. Patients undergoing cardioversion
were younger, more likely male, and more likely from North
America or Europe than patients who did not undergo
cardioversion. Mean weight was higher in patients under-
going cardioversion than those not undergoing car-
dioversion. Patients undergoing cardioversion were also less
likely to have congestive heart failure or a prior stroke or
transient ischemic attack, among other differences noted in
Table 1. Other baseline demographic variables, including
age, sex, geographic location, cardiac risk factors, type of AF
at baseline (paroxysmal or persistent/permanent), and
CHADS2 (congestive heart failure, hypertension, age, dia-
betes, and stroke) score (apixaban: 1.8  1.0; warfarin: 1.9 
1.1), were similar in patients undergoing cardioversion
assigned to either apixaban or warfarin. Cardiac medications
were similar between the groups (Table 1).
Transesophageal echocardiogram. Transesophageal echo-
cardiographic data were available in 171 patients (203 car-
dioversions): 86 patients (97 cardioversions) assigned to
apixaban and 85 patients (106 cardioversions) assigned to
warfarin. None of the patients had evidence of a left atrial
thrombus. Four patients had evidence of spontaneous echo
contrast (1 patient assigned to apixaban and 3 patients
assigned to warfarin).
Clinical outcomes. In the 30 days after cardioversion for
AF, no stroke or systemic emboli occurred (Table 2). The
corresponding 95% conﬁdence intervals for the stroke or
systemic embolism rates were 0% to 1.0% and 0% to 1.2%
for apixaban and warfarin, respectively. One patient assigned
to apixaban experienced an MI compared with 1 patient
assigned to warfarin. Major bleeding occurred in 1 patient
assigned to apixaban and 1 assigned to warfarin.
In the 30 days after cardioversion for AF, death occurred
in 4 patients: 2 patients assigned to apixaban and 2 patients
assigned to warfarin. One patient assigned to apixaban
experienced an MI complicated by cardiogenic shock and
AF, underwent cardioversion, and died on the same day.
Another patient assigned to apixaban experienced a seizure
and was intubated and hospitalized. Central nervous system
imaging revealed a left frontal hemorrhage. The patient
underwent cardioversion but remained in a coma and
died 17 days later. One of 2 patients assigned to warfarin
experienced syncope and head trauma. The patient was
hospitalized and found to have central nervous system
bleeding. The patient later developed AF, underwent
cardioversion, and died 8 days thereafter. A second patient
Table 1
Baseline Characteristics of Patients in the ARISTOTLE Trial Who Underwent at Least 1 Cardioversion by
Treatment Group Compared With Those Who Did Not Undergo Cardioversion
Characteristic
Apixaban
(n ¼ 265)
Warfarin
(n ¼ 275) p Value
Patients Who
Underwent Cardioversion
(n ¼ 540)
Patients Who Did Not
Undergo Cardioversion
(n ¼ 17,648) p Value
Age (yrs) 67.1  9.2 67.3  9.4 0.7749 67.2  9.3 69.1  9.7 <0.0001
Age 75 yrs 56 (21.1) 72 (26.2) 0.1678 128 (23.7) 5,546 (31.4) 0.0001
Female 72 (27.2) 74 (26.9) 0.9456 146 (27.0) 6,269 (35.5) <0.0001
Region 0.9539 <0.0001
North America 125 (47.2) 134 (48.7) 249 (48.0) 4,213 (23.9)
Latin America 9 (3.4) 11 (4.0) 20 (3.7) 3,446 (19.5)
Europe 122 (46.0) 121 (44.0) 243 (45) 7,098 (40.2)
Asia Paciﬁc 9 (3.4) 9 (3.3) 18 (3.3) 2,891 (16.4)
Systolic blood pressure (mm Hg) 131.2  17.1 129.8  18.0 0.3622 130.5  17.6 131.4  16.3 0.2272
Diastolic blood pressure (mm Hg) 79.6  10.5 78.3  10.9 0.2340 78.9  10.7 79.2  10.5 0.5597
Weight (kg) 92.3  20.3 93.4  20.4 0.5226 92.8  20.4 83.8  20.7 <0.0001
Prior myocardial infarction 33 (12.5) 50 (18.2) 0.0624 83 (15.4) 2,499 (14.2) 0.4214
Congestive heart failure 60 (22.6) 64 (23.3) 0.8616 124 (23) 5,408 (30.6) 0.0001
Prior stroke, transient ischemic
attack, or systemic embolism
33 (12.5) 43 (15.6) 0.2876 76 (14.1) 3,459 (19.6) 0.0014
Diabetes 69 (26.0) 75 (27.3) 0.7456 144 (26.7) 4,397 (24.9) 0.3542
Hypertension 232 (87.5) 244 (88.7) 0.6715 476 (88.1) 15,429 (87.4) 0.6180
Prior clinically relevant or
spontaneous bleeding
49 (18.5) 54 (19.6) 0.7348 103 (19.1) 2,933 (16.6) 0.1327
History of fall within previous year 22 (8.7) 10 (3.8) 0.0212 32(6.2) 720 (4.5) 0.0665
Type of atrial ﬁbrillation 0.3979 <0.0001
Paroxysmal 75 (28.3) 87 (31.6) 162 (30.0) 2,622 (14.9)
Persistent or permanent 190 (71.7) 188 (68.4) 378 (70.0) 15,023 (85.1)
Vitamin K antagonist naïve 108 (40.8) 121 (44.0) 0.4456 229 (42.4) 7,566 (42.9) 0.8300
CHADS2 score 1.8  1.0 1.9  1.1 0.1714 1.9  1.0 2.1  1.1 <0.0001
CHADS2 score 0.3137 <0.0001
1 125 (47.2) 119 (43.3) 244 (45.2) 5,938 (33.6)
2 87 (32.8) 86 (31.3) 173 (32.0) 6,339 (35.9)
3 53 (20.0) 70 (25.5) 123 (22.8) 5,371 (30.4)
LVEF 52.9  14.1 52.1  14.3 0.4199 52.5  14.2 54.2  13.2 0.0157
LVEF class 0.1947 0.8034
Normal 62 (73.8) 53 (62.4) 115 (68.0) 3,081 (68.2)
Mild 11 (13.1) 14 (16.5) 25 (14.8) 758 (16.8)
Moderate 5 (6.0) 13 (15.3) 18 (10.7) 438 (9.7)
Severe 6 (7.1) 5 (5.9) 11 (6.5) 239 (5.3)
Medications at time of randomization
ACE inhibitor or ARB 190 (71.7) 202 (73.5) 0.6473 392 (72.6) 12,433 (71.6) 0.6283
Amiodarone 63 (23.8) 56 (20.4) 0.3392 119 (22.0) 1,929 (11.1) <0.0001
Beta-blocker 184 (69.4) 193 (70.2) 0.8499 377 (69.8) 11,098 (63.9) 0.0051
Aspirin 83 (31.3) 88 (32.0) 0.8653 171 (31.7) 5,456 (30.9) 0.7100
Clopidogrel 3 (1.1) 5 (1.8) 0.7249 8 (1.5) 330 (1.9) 0.5103
Digoxin 53 (20.0) 56 (20.4) 0.9162 109 (20.2) 5,713 (32.9) <0.0001
Calcium blocker 85 (32.1) 75 (27.3) 0.2218 160 (29.6) 5,405 (31.1) 0.4541
Lipid-lowering agent 154 (58.1) 152 (55.3) 0.5055 306 (56.7) 7,889 (45.5) <0.0001
Statins 137 (51.7) 132 (48.0) 0.3902 269 (49.8) 7,201 (41.5) 0.0001
Nonsteroidal anti-inﬂammatory drug 34 (12.8) 38 (13.8) 0.7356 72 (13.3) 1,447 (8.3) <0.0001
Gastric antacid drug 64 (24.2) 67 (24.4) 0.9540 131 (24.3) 3,215 (18.5) 0.0008
Maximum number of cardioversions 0.0160
1 214 (80.8) 200 (72.7)
2 40 (15.1) 47 (17.1)
3 11 (4.2) 28 (10.2)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CHADS2 ¼ congestive
heart failure, hypertension, age, diabetes, and stroke; LVEF ¼ left ventricular ejection fraction.
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Table 2
Clinical Outcomes After Any Cardioversion,
Within 30 Days, in Patients Assigned to Either
Warfarin or Apixaban
Outcomes
Warfarin
(n ¼ 412)
Apixaban
(n ¼ 331)
Total
(n ¼ 743)
Stroke or systemic embolism 0 0 0
Myocardial infarction 1 (0.2) 1 (0.3) 2 (0.2)
Major bleeding 1 (0.2) 1 (0.3) 2 (0.2)
Death 2 (0.5) 2 (0.6) 4 (0.5)
Values are n (%).
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1086assigned to warfarin had elective cardioversion for dyspnea.
After cardioversion, hypotension occurred with subsequent
liver and renal failure. The patient died in the hospital 8 days
later.
Because investigators had the opportunity to interrupt
study medication and convert to open-label warfarin for
a cardioversion procedure, a second analysis, an on-
treatment evaluation including only patients on study
medication during the cardioversion, was performed. A total
of 451 patients were included in this analysis. The baseline
characteristics and results of the on-treatment analysis are
shown in Online Table 1. The event rates of this analysis
conﬁrm a low rate of clinical events that did not differ
between the apixaban- and warfarin-treated patients (Online
Table 2).Discussion
The results of this analysis show that clinical events occur-
ring after cardioversion of AF are comparable between
warfarin and apixaban. Of note was that neither stroke nor
systemic embolism was observed. Based on annualized event
rates for the larger trial population of 1.27% and 1.6% for
apixaban and warfarin, respectively, a stroke or systemic
embolism rate after 30 days would be expected to be
0.35% for apixaban and 0.55% for warfarin, so the fact
that neither occurred is reasonable.
The association of stroke with cardioversion of AF has
been recognized for more than 50 years. Case-controlled
studies, which suggested a reduction in stroke with
warfarin after cardioversion, coupled with the assumption
that it may take weeks for a newly-formed thrombus to
become ﬁrmly adherent to the atrial wall and not dislodge
with atrial contraction, resulted in the early recommendation
that adequate anticoagulation be administered for 3 weeks
before cardioversion (13). In addition, because atrial
contractility often takes weeks for complete recovery after
cardioversion (14) and observing the occurrence of stroke
several days after cardioversion (15), anticoagulation was
subsequently recommended for 4 weeks after cardioversion.
This protocol has an established safety record (16).
It may take 2 or more months to achieve adequate anti-
coagulation for cardioversion with warfarin (17). Because
effective anticoagulation is achieved more quickly with
new oral anticoagulants than with warfarin, a hypotheticaladvantage is that the new anticoagulants may shorten the
pre-treatment time needed for adequate anticoagulation
before cardioversion. However, the minimum duration of
therapy required to assure a low risk of an embolic event
remains unknown. In the RE-LY (Randomized Evaluation
of Long-Term Anticoagulation Therapy) trial, which in-
cluded 18,113 patients, 1,319 cardioversions were performed
over a 24-month follow-up period. Although the duration of
anticoagulation before cardioversion was not reported, it was
recommended that patients assigned to dabigatran receive
at least 3 weeks of therapy before cardioversion. In the
ARISTOTLE trial, which included 18,201 patients, fewer
patients underwent cardioversion and cardioversion usually
occurred after months of therapy. In both studies, approxi-
mately 25% of patients underwent transesophageal echo-
cardiography. Although the combined ﬁndings of these
2 analyses indicate a low risk of stroke or systemic emboli
after cardioversion, they do not deﬁne the optimal duration
of pre-cardioversion anticoagulation therapy with new
anticoagulants. Until additional data are reported, elective
cardioversion of AF could be performed with a low risk of
stroke or systemic emboli in patients treated on a long-term
basis with new oral anticoagulants. Although this analysis
suggests that a strategy of treatment with apixaban for at
least several weeks before and after cardioversion appears to
be effective, these remaining uncertainties underscore the
need for more data on the safest approaches toward car-
dioversion in patients receiving apixaban.
Death related to cardioversion is believed to be rare. In the
largest, most recently reported survey of cardioversion, the
Euro Heart Survey reported only 4 deaths in 1,801 patients
around the time of cardioversion (18). In the RE-LY trial, 7
of 1,270 patients (1,983 cardioversions) died in the ﬁrst
30 days of follow-up (9). A Danish study reported 6 deaths
in 385 procedures within 10 days of cardioversion (19). The
occurrence of 4 deaths in our study during the ﬁrst month
after cardioversion, all in patients with serious comorbid
conditions, is consistent with these studies. Death occurred
in seriously ill patients with comorbid conditions. Death was
equally likely in the apixaban and warfarin groups, lessening
the chance that death was related to either therapy.
Study limitations. This analysis was a post-hoc, non-
randomized comparison between apixaban and warfarin, and
important differences may have existed between the groups
that were not detected by our data. The number of patients
undergoing cardioversion was small, and therefore statistical
power to evaluate rare endpoints is excessively low. The
results are descriptive of the sample. Although qualitative
comparisons are made, these must be interpreted with caution
because chance is likely to explain discrepancies. It is uncer-
tain why cardioversion was performed more frequently
in patients assigned to warfarin than apixaban, and this
could have been due to chance. The international normali-
zed ratio at the time of cardioversion was not known.
Post-cardioversion electrocardiograms were not provided, so
the success of cardioversion was not obtained and data were
JACC Vol. 63, No. 11, 2014 Flaker et al.
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macological) performed. Incomplete transesophageal echo-
cardiographic information represents another limitation.
Only 80% of patients assigned to warfarin and 84% of
patients assigned to apixaban were taking the assigned study
drug on the date of cardioversion. Finally, the sample was
derived from a case report form indicating that cardioversion
had been performed. This was initiated by the local investi-
gator. Electrocardiograms before cardioversion were not
reviewed centrally. Although it is possible that some car-
dioversions were performed for cardiac rhythms other than
AF, it is likely that these numbers were small and unlikely to
have any bearing on the results.
Conclusions
Despite these limitations, this analysis showed that stroke or
systemic embolism is uncommon in the ﬁrst 30 days after
cardioversion of AF and rates are comparable between
apixaban and warfarin. Additional data will be helpful to
ﬁrmly establish the efﬁcacy and safety of apixaban in patients
undergoing cardioversion.
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